Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.tranon.2015.03.010 http://scihub22266oqcxt.onion/10.1016/j.tranon.2015.03.010 C4486469!4486469!26055176     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Transl+Oncol 2015 ; 8 (3): 185-95 Nephropedia Template TP {{tp|p=26055176|t=2015. Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment1 |pdf=|usr=}}{{26055176}} gab.com Text Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment1 JO: Transl Oncol http://www.kidney.de/pget.php?&tw=1&pmid=26055176 #FOAvip Polo-like kinases (Plks) are a family of serine-threonine kinases that regulate multiple intracellular processes including DNA replication, mitosis, and stress response. Plk1, the most well understood family member, regulates numerous stages of mitosis and is overexpressed in many cancers. Plk inhibitors are currently under clinical investigation, including phase III trials of volasertib, a Plk inhibitor, in acute myeloid leukemia and rigosertib, a dual inhibitor of Plk1/phosphoinositide 3-kinase signaling pathways, in myelodysplastic syndrome. Other Plk inhibitors, including the Plk1 inhibitors GSK461364A, TKM-080301, GW843682, purpurogallin, and poloxin and the Plk4 inhibitor CFI-400945 fumarate, are in earlier clinical development. This review discusses the biologic roles of Plks in cell cycle progression and cancer, and the mechanisms of action of Plk inhibitors currently in development as cancer therapies. Twit Text FOAVip Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment1 ????Transl Oncol http://www.kidney.de/pget.php?&tw=1&pmid=26055176 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26055176 #FOAvip English Wikipedia <ref>{{Cite pmid|26055176}}</ref> Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment1 #MMPMID26055176 Liu X Transl Oncol 2015[Jun]; 8 (3): 185-95 PMID26055176show ga Polo-like kinases (Plks) are a family of serine-threonine kinases that regulate multiple intracellular processes including DNA replication, mitosis, and stress response. Plk1, the most well understood family member, regulates numerous stages of mitosis and is overexpressed in many cancers. Plk inhibitors are currently under clinical investigation, including phase III trials of volasertib, a Plk inhibitor, in acute myeloid leukemia and rigosertib, a dual inhibitor of Plk1/phosphoinositide 3-kinase signaling pathways, in myelodysplastic syndrome. Other Plk inhibitors, including the Plk1 inhibitors GSK461364A, TKM-080301, GW843682, purpurogallin, and poloxin and the Plk4 inhibitor CFI-400945 fumarate, are in earlier clinical development. This review discusses the biologic roles of Plks in cell cycle progression and cancer, and the mechanisms of action of Plk inhibitors currently in development as cancer therapies. äTargeting Polo-Like Kinases: A Promising Therapeutic Approach for Canc(epmc).pdf DeepDyve Pubget Overpricing